please click on the headlines below to read the complete article
December 2015, Press Release _ Myeloma Canada wish to underline the contribution of Mr. Denis Bilodeau upon his departure.
November 2015, Press Release - Myeloma Canada Receives a Moral Commitment from the Minister of Health and Social Services, Gaétan Barrette
November 2015, Myeloma Canada Research Network and Karyopharm Initiate MCRN 002 (STOMP) Clinical Trial of Oral Selinexor in Multiple Myeloma.
November 2015, The Board of Directors of Myeloma Canada is pleased to announce the election of Dr. Donna Reece to the Board of Directors of the International Myeloma Society (IMS).
November 2015, The Board of Directors of Myeloma Canada proudly announces the appointment of Ms. Cindy Manchulenko to the International Myeloma Foundation’s Nurse Leadership Board (NLB).
October 2015, Myeloma Canada Submits Application for Multi-Million Dollar Research Grant
October 2015, The 2015 Multiple Myeloma March was a resounding success!
September 2015, Myeloma Canada's Monthly Newletter
This is a new therapy in Canada undergoing Health Canada review as well as a funding review for the treatment of multiple myeloma patients who have received at least one prior therapy. to participate to carfilzomib (Kyprolis®) contact us at email@example.com
SIGNATURE BLOOD CANCER MARCH GIVES BACK TO THE MULTIPLE MYELOMA COMMUNITY-WINNIPEG , September 9, 2015 - To mark the organization’s 10-year anniversary, Myeloma Canada will host its 5th Annual Multiple Myeloma March on September 13, 2015. Funds raised for this incurable and little-known form of blood cancer will be dedicated to advance myeloma research through innovative clinical trials across the country and to provide educational services to patients.
The Myeloma Canada Research Network (MCRN) Moves Forward with Significant Funding Support from Karyopharm Therapeutics. Myeloma Canada is very pleased to announce the first major contribution by a pharmaceutical or biotechnology company supporting the formalization of the Myeloma Canada Research Network (MCRN). Karyopharm Therapeutics has made a significant donation to further the development of the MCRN in helping achieve its goal of advancing collaborative, pan-Canadian myeloma clinical trial research.
August 2015, Myeloma Canada's Monthly Newsletter
Myeloma Canada is proud to support Don Wright running his 88th marathon since diagnosis from multiple myeloma in 2003. Vital Options International says 74-year old cancer patient to run his 88th marathon with myeloma in Edmonton, August 23rd.
New Brunswick Government Approves Funding for Pomalyst® - Myeloma Canada applauds New Brunswick’s decision to publicly fund Pomalyst® (pomalidomide) in combination with Decadron® (dexamethasone). Pomalyst® is a treatment option for patients whose disease has progressed despite being treated with traditional therapies. New Brunswick becomes the third jurisdiction after Ontario and Yukon to reimburse Pomalyst®.
Overview of the Myeloma Canada Research Network - The goal of the Myeloma Canada Research Network (MCRN) is to improve patient outcomes by advancing myeloma research across the country. The MCRN is the first and only myeloma research group bringing together Canada’s myeloma research leaders from across Canada. From its beginnings in 2009, it has now grown to a network of over 30 scientists, investigators and clinicians representing 16 myeloma research and treatment centres in nine provinces.
Announcement - Patient Advisory Council - Myeloma Canada is pleased to announce the founding of the Patient Advisory Council (PAC). The Council’s creation was inspired by feedback and comments provided by the patients and caregivers who participated in last year’s pan-Canadian consultation meetings.
Ontario Government Approves Funding for Pomalyst® - Myeloma Canada applauds Ontario’s decision to publicly fund Pomalyst® in combination with Decadron® (dexamethasone). Ontario becomes the first province to reimburse Pomalyst® under the Exceptional Access Program (EAP). Pomalyst® is a treatment option for patients whose disease has progressed despite being treated with traditional therapies.
Criteria updates in the Nova Scotia Formulary regarding Lenalidomide (Revlimid®) - Effective December 29, 2014 - Lenalidomide (Revlimid®) was reviewed by the pCODR Expert Review Committee (pERC) and will be listed with the following new criteria.
Lenalidomide (Revlimid®) has been added to the Newfoundland and Labrador Prescription Drug Program (NLPDP) Benefit List for newly diagnosed multiple myeloma patients, following autologous stem-cell transplantation (ASCT) (for maintenance treatment) - Effective December 1, 2014.
Lenalidomide (Revlimid®) has been added to the New Brunswick Drug Plans Formulary when used as maintenance treatment of patients with newly diagnosed multiple myeloma, following autologous stem-cell transplantation (ASCT), who have stable disease or better, with no evidence of disease progression. - Effective December 12, 2014.
ASH 2014: The Latest on Blood Cancers – From Advances to Patient Advantages - On Sunday, December 7, 2014, at 8 p.m., live from San Francisco, where the 56th American Society of Hematology (ASH) Annual Meeting is taking place, leading blood cancer experts, advocacy organizations and patients will put data into perspective, showcasing how scientific advances help patients. A recording of the webcast will be available on December 8th. We will share a link to the webcast shortly.
The news briefing is being hosted by Myeloma Canada, the International Myeloma Foundation, the Lymphoma Research Foundation, the MDS Foundation on behalf of the MDS Alliance and the National Patient Advocate Foundation. Join the conversation around the briefing using the hashtag#BCBrief14
Government adds 10 medications to Provincial Pharmacare in Prince Edward Island -
Effective November 18, 2014 - Government is enhancing drug programs by adding 10 new drugs - or new indications for existing drugs - to help Islanders battle disease, says Health and Wellness Minister Doug Currie. Find more information on the Catastrophic Drug Program here.
Myeloma Canada Advocacy Summit - On Tuesday, November 4, Myeloma Canada will host its 5th Annual Advocacy Summit. On Wednesday, November 5, it will host Myeloma Canada Awareness Day at Queen's Park in Toronto. Francine Gendron, CEO of Myeloma Canada, and Bill Dempster, CEO of 3Sixty Public Affairs, will welcome multiple myeloma support group members from across Canada to develop advocacy strategies.
For those of you who wish to follow the discussion, we will be live tweeting about the Summit and the Awareness Day (@MyelomaCanada). You can also follow the hashtag #makemyelomamatter. Be part of the conversation.
Click here to access the Advocacy Summit Toolkit.
Multiple Myeloma March 2014 -
On September 21st, eight communities across Canada to raise funds and awareness for this devastating disease. To learn more on each of the cities hosting their annual March, click on the city of your interest
Aldo Del Col, Co-Founder of Myeloma Canada, Elected to the IMF Board of Directors - Aldo Del Col was elected to the Board of Directors of the International Myeloma Foundation (IMF) at the annual meeting held in Los Angeles. Aldo was concurrently appointed to both the International and Scientific committees of the Board.
Announcing The 2014 Board Of Directors For Myeloma Canada - Myeloma Canada is pleased to announce the official composition of its Board of Directors for 2014 following the Annual General Assembly of Members held on February 28, 2014.
Health Canada Approves (Pr)POMALYST(TM) (Pomalidomide Capsules) Providing New Hope For Patients With Progressive Multiple Myeloma - POMALYST Is A New Option For Patients Whose Disease Has Progressed Despite Treatment With Available Therapies
MISSISSAUGA, ON, Feb. 11, 2014 /CNW/ - Health Canada has approved POMALYST™ oral therapy (pomalidomide capsules) in combination with dexamethasone, for patients with multiple myeloma for whom both lenalidomide and bortezomib have failed, who have received at least two prior treatment regimens and have demonstrated disease progression on their last regimen.
Myeloma Canada announces first recipient of the Marion State Memorial Myeloma Canada Nursing Award - Montreal, Quebec – Myeloma Canada is pleased to announce that Nanette Cox-Kennett has been chosen as the recipient of this year’s Marion State Memorial Myeloma Canada Nursing Award. Myeloma Canada, with the support of Celgene Canada, created the award to acknowledge Marion State's extraordinary contributions to the Canadian myeloma community. The winner will be recognized with a special plaque and a donation of $5,000 will be made by Celgene to Myeloma Canada in Marion’s honour.
2013: A year filled with great achievements for Myeloma Canada that bodes well for 2014! - Dear members of the myeloma community, The end of a year is certainly a great occasion to stop and reflect on the activities that took place over the past 12 months. It has only been a few months since I assumed the position of acting president of an organization that fills me with pride and hope (...)
Two studies highlight retrospective analyses of phase III study of Pomalyst®/Imnovid® (pomalidomide) in previously treated multiple myeloma patients presented at ASH - BOUDRY, Switzerland – (Dec. 10, 2013) – Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that updated analyses from MM-003, the company’s phase III study of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination were presented at the American Society of Hematology Annual Meeting in New Orleans, La. Pomalidomide is marketed as POMALYST® in the United States and IMNOVID® in the European Union.
Myeloma Canada says new data at this year’s annual ASH meeting offers a new standard of care for newly diagnosed multiple myeloma patients - New Orleans, LA, USA and Montreal, Canada, December 9, 2013 –– Findings from a new study show continuous treatment with oral Revlimid® (lenalidomide) plus low-dose dexamethasone (Rd) improves survival and other measures of efficacy, compared to a standard of care for newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant.
British Columbia Approves VELCADE® (bortezomib) for all Transplant Eligible Patients - Effective January 1st 2012, the eligibility criteria for using VELCADE® (bortezomib) and dexamethasone with or without cyclophosphamide as induction therapy have been expanded to include all multiple myeloma patients who are eligible for autologous stem cell transplantation (ASCT).
Montreal researchers study new technique that could revolutionize stem-cell transplants - Montreal researchers are taking part in what could become a breakthrough in stem cell transplants, by leading the first transplant of a mismatched donor.
Treatment Trends For Multiple Myeloma – Allogeneic Stem Cell Transplants - This article focuses on Dr. Reece’s findings about allogeneic stem cell transplants.
A Canadian Perspective on the Use of Bisphosphonates in the Clinical Management of Multiple Myeloma
The following paper describes a general consensus on the use of bisphosphonates in MM, but does not reflect a true evidence-based guideline process with a systematic literature review. In addition, patient preference should always be considered in any treatment decision.
Myeloma Canada is affiliated with the International Myeloma Foundation, the world's oldest and largest myeloma organization
Myeloma Canada gratefully acknowledges the generous unrestricted educational grants from our website sponsors: